Coppen A, Abou-Saleh M, Milln P, Bailey J, Wood K
J Affect Disord. 1983 Nov;5(4):353-62. doi: 10.1016/0165-0327(83)90026-5.
In a prospective double-blind trial we examined the affective morbidity and side-effects of 72 patients who were randomly allocated either to continue with their usual dose of lithium or to receive either a 25% or 50% reduction in lithium dosage. Patients who underwent a dosage reduction with consequently lower plasma lithium levels (0.45-0.79 mmol/l) had significantly decreased affective morbidity. Thyroid stimulating hormone levels were also significantly decreased in this group. Total subjective side-effects score and tremor were also reduced. No change in affective morbidity was observed during the trial in patients whose dosage was not altered. These changes were observed in both unipolar and bipolar patients. It was concluded that a once a day dosage with a sustained release lithium preparation that maintained a 12-h plasma level of about 0.6 mmol/l is both more effective and produces less side effects than does conventional dosages.
在一项前瞻性双盲试验中，我们研究了72例患者的情感性发病率和副作用。这些患者被随机分配，要么继续服用常规剂量的锂盐，要么接受锂盐剂量降低25%或50%的治疗。锂盐剂量降低从而导致血浆锂水平较低（0.45 - 0.79 mmol/L）的患者，其情感性发病率显著降低。该组患者的促甲状腺激素水平也显著降低。总的主观副作用评分和震颤也有所减轻。在试验期间，未改变剂量的患者的情感性发病率未观察到变化。这些变化在单相和双相情感障碍患者中均有观察到。得出的结论是，与传统剂量相比，每日一次服用维持12小时血浆水平约为0.6 mmol/L的缓释锂制剂，既更有效，副作用也更少。
